A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine
Immunogenicity And Safety Of An Alum-Adjuvanted Inactivated H7N9 Influenza Vaccine
The aim of this study is to investigate the immunogenicity and safety of the inactivated whole-virion vaccine for teenagers and adults.
The investigators will test the vaccine in participants aged 12-60 years, for a randomized, blind, placebo-controlled, age-stratified clinical study. The investigators designed three dosage groups: 7.5 μg,15 μg and 30 μg of hemagglutinin antigen. According to the age of the subjects, Each group was divided into different age subgroups. Phosphate buffer solution and Aluminum hydroxide adjuvant as placebo controls were both set up in the subgroups.Participants will receive 2 doses of vaccine at 21-day intervals.Safety up to 6 months and changes in hemagglutinin inhibition (HI) titers at 21 days after each vaccination were determined.
調査の概要
状態
条件
研究の種類
入学 (予想される)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
Henan
-
Zhumadian、Henan、中国、463100
- Suiping Center for Disease Control and Prevention
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Over the age of 12 years,healthy population
- Subjects/ (and the guardian) informed consent, voluntarily participated and signed the informed consent form, with the ability to use thermometers, scales and to fill in diary cards as required
- To comply with the requirements of clinical trial program, receive blood test before and after immunization and cooperate with follow-up
Exclusion Criteria:
- A history of influenza A (H7N9) virus infection or suspected infection Abnormal blood routine, blood biochemistry and urine routine examination indexes
- Allergy to any component in the vaccine (allergy history of any previous vaccination), especially for egg allergy
- History of asthma, history of thyroid resection, vascular nerve edema, diabetes mellitus, hypertension can not be controlled by medicine, liver and kidney diseases or malignant tumor history
- Suffered from any serious illness, such as cancer, autoimmune disease, progressive atherosclerotic disease or complications of diabetes, chronic obstructive pulmonary disease, need oxygen therapy for acute or progressive liver or kidney disease, congestive heart-failure etc.
- History of signs disease or symptoms of neurological symptoms
- Suffering from severe chronic diseases (such as Down's syndrome, diabetes, sicklemia or neurological disorders, Green's Barre syndrome)
- Acute attacks of various acute or chronic diseases in the past 7 days
- Known or suspected of respiratory disease, acute infection or chronic disease active period, HIV infection, cardiovascular disease, severe hypertension, malignant tumor during treatment, skin diseases
- Congenital malformations or developmental disorders, genetic defects, severe malnutrition etc
- No spleen, functional absence of spleen, and splenectomy or splenectomy without any condition
- Autoimmune diseases or immunodeficiency have been treated with immunosuppressive agents in the past 6 months
- History of epilepsy, convulsions, or a family history of psychosis
- Abnormal coagulation function (such as coagulation factor deficiency, coagulation disorders, platelet abnormalities), or obvious bruising or coagulopathy
- The blood products were received within 3 months prior to the acceptance of the vaccine
- Received a live vaccine within 14 days prior to receiving the vaccine, or received a subunit or inactivated vaccine within 7 days
- Fever within 3 days prior to vaccination, axillary temperature ≥38 ℃
- Being febrile When inoculating vaccine, axillary temperature >37.0 ℃
- Women are pregnant or in the near future planned pregnancy or pregnancy test positive
- Participants in another clinical trial
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:7.5μg H7N9 Vaccine
Participants will receive 2 doses of 7.5μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
|
The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs,mixed with aluminum hydroxide adjuvant.
|
実験的:15μg H7N9 Vaccine
Participants will receive 2 doses of 15μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
|
このワクチンは、水酸化アルミニウムアジュバントと混合され、発育鶏卵で増殖されたインフルエンザA/上海/2/2013(H7N9)ウイルスの不活化全ビリオン調製物であった。
|
実験的:30μg H7N9 vaccine
Participants will receive 2 doses of 30μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
|
The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs,mixed with aluminum hydroxide adjuvant.
|
プラセボコンパレーター:Aluminum hydroxide adjuvant
Participants will receive 2 doses of aluminum hydroxide adjuvant at 21-day intervals.
|
0.5ml aluminum hydroxide adjuvant
|
プラセボコンパレーター:Phosphate buffer solution
Participants will receive 2 doses of phosphate buffer solution at 21-day intervals.
|
0.5ml phosphate buffer solution
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Reactogenicity Events
時間枠:Continuous observation for 30 days after two inoculations
|
|
Continuous observation for 30 days after two inoculations
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Number of participants that presented seroconversion post injection
時間枠:21 days after two inoculations
|
|
21 days after two inoculations
|
Number of participants that presented seroprotection post injection
時間枠:21 days after two inoculations
|
|
21 days after two inoculations
|
最初の研究注射後の血球凝集阻害力価の幾何平均
時間枠:2回接種から21日後
|
|
2回接種から21日後
|
協力者と研究者
捜査官
- 主任研究者:Ze Chen, PhD、Shanghai Institute Of Biological Products
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
H7N9 インフルエンザの臨床試験
-
Medigen Vaccine Biologics Corp.完了
-
National Institute of Allergy and Infectious Diseases...University of Rochester完了
-
Butantan Institute完了
-
Janssen Research & Development, LLC利用できないA型インフルエンザウイルスのH7N9亜型
-
National Institute of Allergy and Infectious Diseases...完了インフルエンザ A ウイルス、H7N9 サブタイプアメリカ
-
National Institute of Allergy and Infectious Diseases...完了
-
National Institute of Allergy and Infectious Diseases...完了インフルエンザ A ウイルス、H7N9 サブタイプアメリカ
-
NovavaxDepartment of Health and Human Services完了
7.5μg H7N9 Vaccineの臨床試験
-
Butantan Institute完了
-
GlaxoSmithKline完了
-
National Institute of Allergy and Infectious Diseases...完了インフルエンザ A ウイルス、H7N9 サブタイプアメリカ
-
Jiangsu Province Centers for Disease Control and...Wuhan Institute of Biological Products Co., Ltd引きこもった
-
NovavaxDepartment of Health and Human Services完了
-
National Institute of Allergy and Infectious Diseases...完了
-
GlaxoSmithKline完了
-
National Institute of Allergy and Infectious Diseases...完了インフルエンザ A ウイルス、H7N9 サブタイプアメリカ
-
National Institute of Allergy and Infectious Diseases...完了